Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) EBIT Margin (2016 - 2023)

Historic EBIT Margin for Spyre Therapeutics (SYRE) over the last 7 years, with Q2 2023 value amounting to 23146.22%.

  • Spyre Therapeutics' EBIT Margin fell 195585400.0% to 23146.22% in Q2 2023 from the same period last year, while for Mar 2024 it was 39428.92%, marking a year-over-year decrease of 326352800.0%. This contributed to the annual value of 27347.97% for FY2023, which is 237077400.0% down from last year.
  • According to the latest figures from Q2 2023, Spyre Therapeutics' EBIT Margin is 23146.22%, which was down 195585400.0% from 9497.98% recorded in Q1 2023.
  • In the past 5 years, Spyre Therapeutics' EBIT Margin registered a high of 55.88% during Q2 2021, and its lowest value of 23146.22% during Q2 2023.
  • Its 3-year average for EBIT Margin is 6777.45%, with a median of 3587.68% in 2022.
  • Its EBIT Margin has fluctuated over the past 5 years, first crashed by -35318000bps in 2022, then plummeted by -195585400bps in 2023.
  • Spyre Therapeutics' EBIT Margin (Quarter) stood at 560.98% in 2021, then crashed by -1933bps to 11405.95% in 2022, then plummeted by -103bps to 23146.22% in 2023.
  • Its EBIT Margin stands at 23146.22% for Q2 2023, versus 9497.98% for Q1 2023 and 11405.95% for Q4 2022.